Compare BridgeBio Pharma Inc (BBIO) vs Workday Inc (WDAY) Price & Performance

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Workday (WDAY) trades at $179.64, up 5.52% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with moving averages supporting an uptrend, while RSI levels indicate potential overbought conditions. Fundamentally, the company has consistently beaten earnings expectations, with Q1 2026 EPS of $2.66 surpassing estimates of $2.51. Revenue growth is robust, projected to rise from $8.45B in 2025 to $9.9B in 2026, though net income margins have fluctuated. Recent news highlights partnerships and product launches, such as the Workday Adaptive Planning FedRAMP authorization announced on July 23, 2026.

The outlook for WDAY is positive, driven by earnings beats and strategic AI integrations, but elevated valuation ratios like a P/E of 55.96 pose risks. Investors should weigh growth potential against competitive pressures and market volatility, with analyst consensus leaning bullish but caution advised near technical resistance levels.